The role of ifosfamide plus cisplatin-ba
โ
Robert J. Motzer; Karen Cooper; Nancy L. Geller; Dean F. Bajorin; Ethan Dmitrovs
๐
Article
๐
1990
๐
John Wiley and Sons
๐
English
โ 537 KB
A prospective study of four cycles of etoposide with ifosfamide and cisplatin (VIP) chemotherapy was conducted in 42 germ cell tumor (GCT) patients who were refractory to cisplatin with etoposide/vinblastine-based therapy. Forty patients were evaluable for response. Ten patients (25%) had a complete